EGFR mutation

You have access
Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in Lung Cancer
JI SUN PARK, HA YOUNG PARK and YUNSEON CHOI

Anticancer Research June 2024, 44 (6) 2681-2687; DOI: https://doi.org/10.21873/anticanres.17075
You have access
Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data
SARAH SHARMAN MOSER, LIOR APTER, JOSIE SOLOMON, GABRIEL CHODICK, MIRIANA WOLLNER and NAVA SIEGELMANN-DANIELI

Anticancer Research January 2024, 44 (1) 257-265; DOI: https://doi.org/10.21873/anticanres.16809
Open Access
Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer
TOSHIHIRO SHIOZAWA, TAKESHI NUMATA, TOMOHIRO TAMURA, TAKEO ENDO, TAKAYUKI KABURAGI, YUSUKE YAMAMOTO, HIDEYASU YAMADA, NORIHIRO KIKUCHI, KAZUHITO SAITO, MASAHARU INAGAKI, KOICHI KURISHIMA, YASUNORI FUNAYAMA, KUNIHIKO MIYAZAKI, NOBUYUKI KOYAMA, KINYA FURUKAWA, HIROYUKI NAKAMURA, SHINJI KIKUCHI, HIDEO ICHIMURA, YUKIO SATO, IKUO SEKINE, HIROAKI SATOH and NOBUYUKI HIZAWA

Anticancer Research May 2022, 42 (5) 2583-2590; DOI: https://doi.org/10.21873/anticanres.15736
You have access
Real-world Afatinib Outcomes in Advanced Non–small Cell Lung Cancer Harboring EGFR Mutations
CHI-HAN CHEN, JOHN WEN-CHENG CHANG, CHING-FU CHANG, CHEN-YANG HUANG, CHENG-TA YANG, CHIH-HSI SCOTT KUO, YUEH-FU FANG, PING-CHIH HSU and CHIAO-EN WU

Anticancer Research April 2022, 42 (4) 2145-2157; DOI: https://doi.org/10.21873/anticanres.15697
You have access
Significance of Mitochondrial DNA Haplogroup on Epidermal Growth Factor Receptor Mutation in Japanese Patients With Lung Adenocarcinoma
TSUNAYUKI OTSUKA, KAZUHIRO UEDA, TATSUHIKO FURUKAWA, CHIHAYA KORIYAMA, ITURO INOUE and MASAMI SATO

Anticancer Research August 2021, 41 (8) 3997-4004; DOI: https://doi.org/10.21873/anticanres.15197
You have access
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
MOTOHIRO TAMIYA, AKIHIRO TAMIYA, HIDEKAZU SUZUKI, KAZUNORI MORIIZUMI, KENJI NAKAHAMA, YOSHIHIKO TANIGUCHI, KEI KUNIMASA, MADOKA KIMURA, TAKAKO INOUE, HANAKO KUHARA, KAZUMI NISHINO, TOMONORI HIRASHIMA, SHINJI ATAGI, FUMIO IMAMURA and TORU KUMAGAI

Anticancer Research July 2019, 39 (7) 3923-3929; DOI: https://doi.org/10.21873/anticanres.13544
You have access
Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs
SATOSHI WATANABE, OU YAMAGUCHI, AI MASUMOTO, YURI MAENO, YOSUKE KAWASHIMA, OSAMU ISHIMOTO, SHUNICHI SUGAWARA, HIROHISA YOSHIZAWA, TOSHIAKI KIKUCHI, TOSHIHIRO NUKIWA and KUNIHIKO KOBAYASHI

Anticancer Research August 2018, 38 (8) 4699-4704; DOI: https://doi.org/10.21873/anticanres.12776
You have access
Detection of EGFR Gene Mutation by Mutation-oriented LAMP Method
NAOYUKI MATSUMOTO, AKIRA KUMASAKA, TOMOHIRO ANDO and KAZUO KOMIYAMA

Anticancer Research April 2018, 38 (4) 2093-2099;
You have access
Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression
KENICHI KOBAYASHI, MASAHIRO SEIKE, FENFEI ZOU, RINTARO NORO, MIKA CHIBA, ARIMI ISHIKAWA, SHINOBU KUNUGI, KAORU KUBOTA and AKIHIKO GEMMA

Anticancer Research February 2018, 38 (2) 753-762;
You have access
Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab
BEATRIZ WILLS, ANDRÉS F. CARDONA, LEONARDO ROJAS, ALEJANDRO RUIZ-PATIÑO, OSCAR ARRIETA, NOEMÍ REGUART, HERNÁN CARRANZA, CARLOS VARGAS, JORGE OTERO, LUIS CORRALES, CLAUDIO MARTÍN, MAURICIO CUELLO, LUIS EDUARDO PINO, CHRISTIAN ROLFO, RAFAEL ROSELL, ZYANYA LUCIA ZATARAIN-BARRÓN and on behalf of The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)

Anticancer Research November 2017, 37 (11) 6429-6436;

Main menu

User menu

Search

EGFR mutation

Pages